Current Treatment Options in Neurology最新文献_第3页

TINNITUS. A Non-invasive Neuromodulatory Perspective TINNITUS。非侵入性神经调节视角

IF 2 4区医学

Current Treatment Options in Neurology Pub Date : 2024-06-18 DOI: 10.1007/s11940-024-00802-w

Simone Rossi, Marco Mandalà

{"title":"TINNITUS. A Non-invasive Neuromodulatory Perspective","authors":"Simone Rossi, Marco Mandalà","doi":"10.1007/s11940-024-00802-w","DOIUrl":"https://doi.org/10.1007/s11940-024-00802-w","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of the Review</h3><p>Chronic tinnitus affects millions of people worldwide, but it remains an unmet clinical problem, particularly from a therapeutic perspective.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>Neuroimaging and neurophysiological investigations have consistently unveiled that tinnitus can be considered as a form of maladaptive plasticity taking place not only in primary and associative auditory areas but also involving large-scale brain networks. Based on these premises, treatment strategies that aim to manipulate in a controllable way plastic capabilities of the brain are being under investigation as emerging treatments.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>here, we review the rationale for using so called Non-Invasive Brain stimulation (NiBS) techniques, such as navigated repetitive transcranial magnetic stimulation (rTMS) and other forms of transcranial electrical stimulation (tES) or peripheral stimulations, to alleviate tinnitus. We also provide an overview of available clinical results of these various non-invasive neuromodulatory approaches, trying to identify how to translate their unquestionable therapeutic potential into real-life contexts, beyond the lab boundaries.</p>","PeriodicalId":10975,"journal":{"name":"Current Treatment Options in Neurology","volume":"78 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141501466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Delving Into the Significance of Brain’s Collateral Circulation in the Era of Revascularization Therapy 探讨血管重建疗法时代大脑侧支循环的意义

IF 2 4区医学

Current Treatment Options in Neurology Pub Date : 2024-05-04 DOI: 10.1007/s11940-024-00794-7

Marilena Mangiardi, Sergio Soeren Rossi, Adriano Bonura, Gianmarco Iaccarino, Michele Alessiani, Sabrina Anticoli, Gianluca De Rubeis, Enrico Pampana, Francesca Romana Pezzella

{"title":"Delving Into the Significance of Brain’s Collateral Circulation in the Era of Revascularization Therapy","authors":"Marilena Mangiardi, Sergio Soeren Rossi, Adriano Bonura, Gianmarco Iaccarino, Michele Alessiani, Sabrina Anticoli, Gianluca De Rubeis, Enrico Pampana, Francesca Romana Pezzella","doi":"10.1007/s11940-024-00794-7","DOIUrl":"https://doi.org/10.1007/s11940-024-00794-7","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of review</h3><p>This narrative review summarized the major studies focusing on the association between revascularization therapies (intravenous thrombolysis and endovascular thrombectomy) and collateral circulation status in terms of outcome and safety. Our aim is to elucidate, drawing upon the latest scientific evidence, the pivotal role that collateral circulation plays in shaping the prognosis and potential therapeutic in patients with ischemic stroke.</p><h3 data-test=\"abstract-sub-heading\">Recent findings</h3><p>The data currently available suggest that pre-treatment assessment of collateral circulation may be crucial, as a good collateral circulation status appears to be associated with better outcomes in terms of both early revascularization and long-term disability. There is limited literature about the assessment of collateral circulation prior to acute reperfusion therapy.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>The role of the intracranial collateral circulation is gaining increasing attention in the field of ischemic stroke, both in terms of outcome prognosis and therapeutic interventions. These findings need to be confirmed by more structured randomized controlled trials (RCTs), but they suggest that investigating therapeutic strategies to maintain and support collateral circulation may represent the future of ischemic stroke therapy.</p>","PeriodicalId":10975,"journal":{"name":"Current Treatment Options in Neurology","volume":"83 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140883527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Updates in Fluid, Tissue, and Imaging Biomarkers for Dementia with Lewy Bodies and Implications for Biologically Based Disease Definitions 路易体痴呆的体液、组织和成像生物标记物的最新进展及其对基于生物学的疾病定义的影响

IF 2 4区医学

Current Treatment Options in Neurology Pub Date : 2024-05-04 DOI: 10.1007/s11940-024-00791-w

Samantha K. Holden

{"title":"Updates in Fluid, Tissue, and Imaging Biomarkers for Dementia with Lewy Bodies and Implications for Biologically Based Disease Definitions","authors":"Samantha K. Holden","doi":"10.1007/s11940-024-00791-w","DOIUrl":"https://doi.org/10.1007/s11940-024-00791-w","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>Dementia with Lewy bodies (DLB) remains underrecognized and underdiagnosed due to its clinical and pathological heterogeneity. Diagnosis currently relies on recognition of clinical features and imaging and neurophysiologic biomarkers. However, clinical features are less obvious in mixed neurodegenerative pathologies, advanced imaging techniques are often inaccessible, and current DLB indicative biomarkers do not directly identify Lewy pathology.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>Seed amplification assay techniques have allowed for in vivo detection of pathological alpha-synuclein protein in the cerebrospinal fluid, blood, and dermal biosamples. Incorporation of co-pathology markers and refinement of the application and interpretation of existing tests for DLB, including brain and cardiac imaging, are also ongoing. Strategic combinations of Lewy biomarkers with other markers of neurodegeneration and neuroinflammation could create individualized patient profiles for diagnosis, prognosis, treatment selection, and response monitoring.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Continued validation and technical harmonization efforts will be needed prior to widespread clinical application of new Lewy body biomarkers. Combining existing and novel DLB and co-pathology biomarkers, along with thorough clinical evaluation, will lead to increased reliability and accuracy of etiological dementia diagnosis. Use of biomarker profiles and biologically based disease definitions will improve care and accelerate treatment discovery for people living with DLB.</p>","PeriodicalId":10975,"journal":{"name":"Current Treatment Options in Neurology","volume":"53 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140883791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Efficiency of Established Diagnostic and Therapeutic Approaches in the Treatment of Trigeminal Neuralgia 治疗三叉神经痛的既有诊断和治疗方法的效率

IF 2 4区医学

Current Treatment Options in Neurology Pub Date : 2024-05-03 DOI: 10.1007/s11940-024-00795-6

Fazladin T. Temurov, Asel A. Biseytova, Bakhytkul A. Ernazarova, Bibifatima D. Mukhambetova, Asan S. Ubaydullaev

{"title":"The Efficiency of Established Diagnostic and Therapeutic Approaches in the Treatment of Trigeminal Neuralgia","authors":"Fazladin T. Temurov, Asel A. Biseytova, Bakhytkul A. Ernazarova, Bibifatima D. Mukhambetova, Asan S. Ubaydullaev","doi":"10.1007/s11940-024-00795-6","DOIUrl":"https://doi.org/10.1007/s11940-024-00795-6","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>The research aims to determine the effectiveness of the main approaches in the diagnosis and treatment of trigeminal neuralgia. Analysis, synthesis, comparison, and generalisation were used as methods of studying the object of research.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>According to the results of the study, the most effective method of diagnosis was found to be examination and history taking. Correct performance of these actions allows to find out whether the nature of the patient’s pain is a symptom of trigeminal neuralgia. For this purpose, the location, nature, and triggering factors of the pain are determined. At the same time, pain characteristics are compared to exclude other diseases that are also accompanied by pain in the face. Among the instrumental diagnostic methods, magnetic resonance imaging has proven to be the most effective, allowing to determine the form of neuralgia and its causes. To determine the effectiveness of treatment methods, the parameters of pain relief rate, duration of the therapeutic effect and the presence of side effects were used. The most effective approach in the conservative treatment of trigeminal neuralgia was determined to be a complex drug therapy, including anticonvulsants, muscle relaxants, antispasmodics, and physiotherapy procedures. The most effective method of surgical intervention is microvascular decompression, which provides immediate pain relief in most cases and has the longest-lasting effect compared to other methods.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Rhizotomy was defined as a less effective procedure, but its advantage was its minimally invasive nature. Even though trigeminal neuralgia is a recurrent disease, the right treatment approach can maximise the duration of remission and return the patient to a normal lifestyle.</p>","PeriodicalId":10975,"journal":{"name":"Current Treatment Options in Neurology","volume":"14 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140883600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of Malignant Cerebral Edema in Acute Ischemic Stroke 急性缺血性脑卒中恶性脑水肿的治疗

IF 2 4区医学

Current Treatment Options in Neurology Pub Date : 2024-04-19 DOI: 10.1007/s11940-024-00793-8

Maximiliano A. Hawkes, Alejandro A. Rabinstein

{"title":"Treatment of Malignant Cerebral Edema in Acute Ischemic Stroke","authors":"Maximiliano A. Hawkes, Alejandro A. Rabinstein","doi":"10.1007/s11940-024-00793-8","DOIUrl":"https://doi.org/10.1007/s11940-024-00793-8","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of review</h3><p>To provide an updated summary on the diagnosis and treatment of patients with malignant cerebral edema after ischemic stroke.</p><h3 data-test=\"abstract-sub-heading\">Recent findings</h3><p>The risk of malignant middle cerebral artery (MCA) stroke is highest in young patients with large vessel occlusion and unsuccessful revascularization. Several scores are available for risk stratification. Treatment includes supportive care, close neurologic monitoring, and hyperosmolar therapy. Yet, the main therapeutic decision is whether to proceed with decompressive craniectomy. Multiple randomized clinical trials and several meta-analyses have demonstrated that decompressive hemicraniectomy is the single most important intervention associated with survival. Survivors may face severe disability regardless of surgical treatment, and the definition of acceptable outcome in this context remains elusive.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Malignant MCA infarcts are life-threatening and invariably cause disability, most often severe. Neurologic deterioration requires airway management and hyperosmolar therapy. Decompressive hemicraniectomy is a lifesaving procedure; approximately 50% of surgically treated patients younger than 60 years can regain independent ambulation, and one nearly in five may become functionally independent at 1 year. Older patients face a much worse functional prognosis; surgical decisions in these patients should be assessed case by case.</p>","PeriodicalId":10975,"journal":{"name":"Current Treatment Options in Neurology","volume":"3 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140623403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Updates on Facioscapulohumeral Muscular Dystrophy (FSHD) 面阔肱肌营养不良症 (FSHD) 的最新进展

IF 2 4区医学

Current Treatment Options in Neurology Pub Date : 2024-04-02 DOI: 10.1007/s11940-024-00790-x

Amanda X. Y. Chin, Zhi Xuan Quak, Yee Cheun Chan, Amy M. L. Quek, Kay W. P. Ng

{"title":"Updates on Facioscapulohumeral Muscular Dystrophy (FSHD)","authors":"Amanda X. Y. Chin, Zhi Xuan Quak, Yee Cheun Chan, Amy M. L. Quek, Kay W. P. Ng","doi":"10.1007/s11940-024-00790-x","DOIUrl":"https://doi.org/10.1007/s11940-024-00790-x","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of review</h3><p>This review aims to provide a summary of the pathophysiology, clinical presentation and management options for facioscapulohumeral dystrophy (FSHD). We discuss current management options and delve into updates about developments in targeted therapy.</p><h3 data-test=\"abstract-sub-heading\">Recent findings</h3><p>New breakthroughs in FSHD research have led to a further understanding of aberrant DUX4 protein expression in the underlying pathophysiology of FSHD. This has paved the way for the development of targeted therapies aimed at targeting DUX4 expression or its downstream effects. Therapeutic strategies for FSHD primarily target DUX4 through three main avenues: small molecules, antisense oligonucleotide therapeutics and CRISPR-based approaches. This review discusses these strategies further. Presently, all prospective targeted therapies are in the pre-clinical phase, except for losmapimod, which is currently undergoing a phase 3 clinical trial.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Given the absence of approved disease-modifying treatments for FSHD, the primary approach for management currently involves multidisciplinary supportive measures which are limited. Recent developments in the form of targeted therapies and strategies for the definitive treatment of FSHD indicate a promising era.</p>","PeriodicalId":10975,"journal":{"name":"Current Treatment Options in Neurology","volume":"49 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140566277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Update on Treatment of Idiopathic (and Non-Idiopathic) Orbital Inflammation 特发性（和非特发性）眼眶炎症的最新治疗方法

IF 2 4区医学

Current Treatment Options in Neurology Pub Date : 2024-03-26 DOI: 10.1007/s11940-024-00788-5

Elana Meer, Michael K. Yoon, Jonathan E. Lu

{"title":"Update on Treatment of Idiopathic (and Non-Idiopathic) Orbital Inflammation","authors":"Elana Meer, Michael K. Yoon, Jonathan E. Lu","doi":"10.1007/s11940-024-00788-5","DOIUrl":"https://doi.org/10.1007/s11940-024-00788-5","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of review</h3><p>This review aims to provide a critical appraisal of current diagnostic and therapeutic strategies for patients with orbital inflammatory disease (OID). We present the reader with a review of clinical, imaging, laboratory, and biopsy based assessment of OID and review the current treatment modalities utilized including corticosteroids, corticosteroid-sparing (immunomodulatory) agents, radiation, antibiotics, and disease specific therapy.</p><h3 data-test=\"abstract-sub-heading\">Recent findings</h3><p>Two major developments and trends have emerged in the management of orbital inflammation. First, improved understanding and distinction of inflammation subtypes (myositis, dacryoadenitis, or infiltrative) allows for more nuanced workup and treatment. Second, immunomodulatory agents have shown promise in achieving disease control in cases of truly idiopathic or corticosteroid-resistant OID. Together, these advances have led to fewer adverse effects and better efficacy.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>The optimal treatment of OID depends on distinguishing between nonspecific and specific inflammation. Nonspecific inflammation tends to respond to corticosteroid therapy with a lower chance of relapse, while specific orbital inflammation often requires targeting the underlying disease with steroid-sparing therapy and immunomodulatory agents.</p>","PeriodicalId":10975,"journal":{"name":"Current Treatment Options in Neurology","volume":"154 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140299468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Distinguishing Benign Rashes From Severe Skin Reactions From Anti-Seizure Medications 区分良性皮疹和抗癫痫药物引起的严重皮肤反应

IF 2 4区医学

Current Treatment Options in Neurology Pub Date : 2024-03-21 DOI: 10.1007/s11940-024-00785-8

Ram Mani, Ahmad Almelegy, Thu Minh Truong, Gaurav N. Pathak, Mary L. Wagner, Cindy Wassef

{"title":"Distinguishing Benign Rashes From Severe Skin Reactions From Anti-Seizure Medications","authors":"Ram Mani, Ahmad Almelegy, Thu Minh Truong, Gaurav N. Pathak, Mary L. Wagner, Cindy Wassef","doi":"10.1007/s11940-024-00785-8","DOIUrl":"https://doi.org/10.1007/s11940-024-00785-8","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of review</h3><p>This review describes risk factors for severe skin reactions to antiseizure medications (ASMs), the usage of updated tests to predict those with increased risk of a severe cutaneous reaction, and guides how to choose specific ASMs and dosing to lower the risk for these reactions. Information is given regarding specific mild versus severe reactions, initial diagnostic evaluation, and treatment. A table listing the risk of mild and severe cutaneous reaction risks as well as the management of potential seizures that may occur while stopping the culprit ASM are provided.</p><h3 data-test=\"abstract-sub-heading\">Recent findings</h3><p>Five new ASMs have joined the total of 26 FDA-approved ASMs since 2018. Cenobamate had three patients develop a drug reaction with eosinophilia and systemic symptoms. A lower starting dosing and slower titration have resulted in no further published cases. Based on limited data, rash risk is low for fenfluramine, ganaxalone, and stiripentol. It is low-moderate for Epidiolex. Molecular tests can predict severe reactions.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Skin reactions are a relatively common side effect of ASMs with aromatic ASMs having the greatest risk. Identifying and informing high-risk patients when to seek medical attention, stopping the culprit ASM when a severe reaction looks possible, and providing appropriate medical triage can reduce morbidity and mortality from severe skin and systemic reactions.</p>","PeriodicalId":10975,"journal":{"name":"Current Treatment Options in Neurology","volume":"82 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140202161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management Strategies for Atypical Parkinsonism 非典型帕金森病的管理策略

IF 2 4区医学

Current Treatment Options in Neurology Pub Date : 2024-03-21 DOI: 10.1007/s11940-024-00787-6

Vasilios C. Constantinides, Nikolaos Giagkou, Maria-Evgenia Brinia, Christos Koros, Leonidas Stefanis, Maria Stamelou

{"title":"Management Strategies for Atypical Parkinsonism","authors":"Vasilios C. Constantinides, Nikolaos Giagkou, Maria-Evgenia Brinia, Christos Koros, Leonidas Stefanis, Maria Stamelou","doi":"10.1007/s11940-024-00787-6","DOIUrl":"https://doi.org/10.1007/s11940-024-00787-6","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>Atypical parkinsonism is a term usually used to describe three neurodegenerative parkinsonian disorders: progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA). In contrast to Parkinson’s disease, these disorders have a poor prognosis and present with a multitude of diverse symptoms, including parkinsonism, dystonia, myoclonus, gait disorders, dysarthria, dysphagia, sleep, cognitive, and behavioral disorders. In the absence of an approved disease-modifying treatment, symptomatic treatment is the mainstay of management. The purpose of this review is to present an overview of the management of these complex disorders, with a particular focus on a holistic and multidisciplinary approach.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>In addition to presenting the most significant pharmacological interventions for symptom management, data regarding non-pharmacological interventions are analyzed. Important non-pharmacological clinical practice questions such as breaking the news, palliative care, and end-of-life issues are discussed, in an effort to present an overview of the management of atypical parkinsonism from diagnosis to the most advanced stages of these diseases.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Management of atypical parkinsonian disorders includes symptomatic pharmacological and non-pharmacological interventions, in addition to addressing issues such as informing the patient of the diagnosis, palliative care, and end-of-life issues, which require a multidisciplinary approach.</p>","PeriodicalId":10975,"journal":{"name":"Current Treatment Options in Neurology","volume":"25 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140201950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment Approaches in Pediatric Relapsing Autoimmune Encephalitis 小儿复发性自身免疫性脑炎的治疗方法

IF 2 4区医学

Current Treatment Options in Neurology Pub Date : 2024-03-21 DOI: 10.1007/s11940-024-00786-7

{"title":"Treatment Approaches in Pediatric Relapsing Autoimmune Encephalitis","authors":"","doi":"10.1007/s11940-024-00786-7","DOIUrl":"https://doi.org/10.1007/s11940-024-00786-7","url":null,"abstract":"<h3>Abstract</h3> <span> <h3>Purpose of review</h3> <p>Autoimmune encephalitis (AE) is increasingly recognized as a treatable cause of encephalitis in children. While prior observational studies demonstrate improved motor outcomes with early immunotherapy, less is known about long-term management and treatment for relapsing disease. In this review, we present current treatment approaches to pediatric AE, in particular relapse risk and treatment for relapsing AE in children.</p> </span> <span> <h3>Recent findings</h3> <p>A recent meta-analysis of anti-NMDAR encephalitis demonstrated that disease onset in adolescence was associated with an increased odds of relapse whereas treatment with rituximab and IVIG for 6 months or longer were associated with a non-relapsing course. However, no specific pediatric sub-analyses were reported. A single-center study on adult and pediatric AE showed that rituximab use was associated with a reduction in time to relapse and recurring relapses although the data for the pediatric cohort did not achieve statistical significance.</p> </span> <span> <h3>Summary</h3> <p>The use of second-line immunotherapy during the initial attack may reduce the risk for relapsing disease in pediatric AE. Larger studies are needed to investigate relapse risk and treatment in both anti-NMDAR and non-NMDAR encephalitis in children.</p> </span>","PeriodicalId":10975,"journal":{"name":"Current Treatment Options in Neurology","volume":"12 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140201959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0